---
title: "Entero Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/266625854.md"
datetime: "2025-11-19T22:15:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/266625854.md)
  - [en](https://longbridge.com/en/news/266625854.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/266625854.md)
generator: "portal-rs"
---

# Entero Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.75.

EBIT: As of FY2025 Q3, the actual value is USD -898.72 K.

### Segment Revenue

-   Entero Therapeutics, Inc. did not report any revenue for the three and nine months ended September 30, 2025 and 2024.

### Operational Metrics

-   **Net Loss**: For the three months ended September 30, 2025, the net loss was $1,152,809, compared to $2,580,971 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $3,410,700, compared to $5,821,067 for the same period in 2024.
-   **Research and Development Expenses**: For the three months ended September 30, 2025, research and development expenses were $6,673, compared to $206,999 for the same period in 2024. For the nine months ended September 30, 2025, research and development expenses were $32,080, compared to $882,522 for the same period in 2024.
-   **General and Administrative Expenses**: For the three months ended September 30, 2025, general and administrative expenses were $928,114, compared to $1,685,608 for the same period in 2024. For the nine months ended September 30, 2025, general and administrative expenses were $2,362,957, compared to $13,535,241 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the nine months ended September 30, 2025, net cash used in operating activities was $1,729,201, compared to $9,046,305 for the same period in 2024.
-   **Net Cash Provided by Investing Activities**: For the nine months ended September 30, 2025, net cash provided by investing activities was $336,427, compared to $88,169 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: For the nine months ended September 30, 2025, net cash provided by financing activities was $3,725,000, compared to $5,613,152 for the same period in 2024.

### Unique Metrics

-   **Assets Held for Sale**: As of September 30, 2025, assets held for sale were valued at $83,170,009, with liabilities held for sale at $23,672,708.

### Future Outlook and Strategy

-   **Core Business Focus**: Entero Therapeutics plans to continue the development of its Adrulipase program in 2026, focusing on the treatment of exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients.
-   **Non-Core Business**: The company is seeking to dispose of certain assets and liabilities of its IMGX subsidiary, including Latiglutenase and CypCel, as part of a strategic shift.
-   **Priority**: The company is evaluating all potential strategic options, including a merger, reverse merger, sale, wind-down, liquidation and dissolution or other strategic transaction.

### Related Stocks

- [ENTO.US](https://longbridge.com/en/quote/ENTO.US.md)
- [GRDX.US](https://longbridge.com/en/quote/GRDX.US.md)

## Related News & Research

- [GridAI amends 8-K to correct share and pre-funded warrant allocation in $8.5 million private placement](https://longbridge.com/en/news/291977566.md)
- [GridAI Technologies Announces Private Equity Financing Agreement](https://longbridge.com/en/news/291848067.md)
- [GridAI Technologies prices USD 8.5 million private placement of shares and warrants](https://longbridge.com/en/news/291846493.md)
- [GridAI Q2 FY26 net loss widens to $13.04 million; revenue turns to $85,876](https://longbridge.com/en/news/296655135.md)
- [GridAI Technologies Secures $7.79 Million in Private Placements With Warrants](https://longbridge.com/en/news/286459338.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**